In real dollars, these payers’ combined savings would have nearly reached $20 billion just in 2018, the analysis shows.

HHS has awarded $25 million to 80 organizations that are battling the opioid epidemic in rural communities by providing prevention, treatment and recovery services.

Judging by work RVUs, U.S. physicians and other clinicians are getting decent raises every year without lifting their billable productivity enough to pay for it, AMGA’s latest survey suggests.

If they hope to survive the COVID healthcare economy, many independent hospitals may need to cut their workforces, slash their expenses, reduce their investments, pull the plug on some clinical service lines—or all of the above.

After reviewing provider reimbursements, an investigative reporter suggests the Trump administration’s low-profile initiative hasn’t been uniformly poor so much as undeniably erratic.

Two days before HHS was to stop accepting providers’ applications for a second, $15 billion round of CARES Act relief funding, the agency is announcing it will extend the deadline to Sept. 13.

Comparing the financials of more than 200 private equity-acquired hospitals with those of more than 500 matched controls, Harvard researchers have found Big Money’s backing translates into bigger income.

Unless there’s a turnaround from the high costs and low revenues of the COVID healthcare economy, more than 70% of nursing homes and 64% of assisted living communities will not be here a year from now.  

The authors suggest requiring drugmakers, hospitals and doctors to refund CMS and/or making pharma companies right-size drug containers.

Millennials, Gen Xers and Baby Boomers fall fairly close to one another in how they view several aspects of life with COVID. One in which the divide is wide: the desire for a “digital detox.”

HHS says bullseye recipients are pediatric hospitals that are unaffiliated with larger health systems, serve vulnerable populations and have taken revenue hits during the COVID crisis.

Former CMS acting head Andy Slavitt, MBA, is virtually fist-bumping the FDA for greenlighting Yale’s fast and cheap SalivaDirect protocol for COVID testing.